Background: Several prognostic and predictive biomarkers for decision-making regarding neo-adjuvant
(NAC) and adjuvant treatment in estrogen receptor (ER)-positive breast cancer patients
have been developed. However, their ability to predict patient prognosis and treatment
outcomes is poor. Hence, validated markers for predicting prognosis and treatment
outcomes need to be developed. Expression of human epidermal growth factor receptor
2 (HER2) is evaluated by immunohistochemistry (IHC), and its gene amplification by
Fluorescence in situ Hybridization (FISH) is not always examined. In our hospital,
HER2 FISH has been assessed in almost all patients including those with HER2 status
0 and 1 (i.e., low-HER2 expression). Moreover, anti HER2 chemotherapy is administered
if the patient’s status is low-HER2 FISH-positive. In this report, we retrospectively
investigated the ratio and characteristics of low-HER2 FISH-positive patients and
compared their recurrence-free survival (RFS) with that of luminal A FISH-negative
patients to examine whether evaluation of HER2 FISH in luminal A breast cancer could
improve survival.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2020 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
